Skip to content

Epigenomics Lung Cancer Test for China

Epigenomics Enters Agreement with Biochain on Lung Cancer Test for China

March 30, 2016

Epigenomics AG :

* Enters strategic license and development agreement with Biochain on novel, blood-based lung cancer test for China

* Will receive undisclosed upfront, milestone and minimum annual payments as well as mid single-digit royalty on future revenues

* Biochain will initiate a clinical trial to validate lung cancer detection test with goal to gain market approval by CFDA

* Trial is expected to start in 2016

Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Scroll To Top